Stay updated on BBP-398 + Osimertinib in EGFR+ NSCLC: Clinical Trial
Sign up to get notified when there's something new on the BBP-398 + Osimertinib in EGFR+ NSCLC: Clinical Trial page.

Latest updates to the BBP-398 + Osimertinib in EGFR+ NSCLC: Clinical Trial page
- ChecktodayNo Change Detected
- Check7 days agoChange DetectedThe page revision tag was updated to v3.6.6, replacing the previous v3.6.5 on the study record.SummaryDifference0.1%

- Check14 days agoNo Change Detected
- Check28 days agoChange DetectedThe page revision was updated from v3.6.4 to v3.6.5, indicating a new version of the ClinicalTrials.gov page was published. This appears to be a minor update or correction rather than a change to the study data or eligibility criteria.SummaryDifference0.1%

- Check50 days agoChange DetectedRevision tag updated from v3.6.3 to v3.6.4. This indicates a minor page refresh or metadata update on the study details page without altering the study information.SummaryDifference0.1%

- Check71 days agoChange DetectedThe revision label on the page updated to v3.6.3, replacing the previous v3.6.0.SummaryDifference0.1%

- Check85 days agoChange DetectedThe study record now shows recruitment has ended, indicating the trial is not enrolling any more participants. Added navigation/help items (How to Read a Study Record, Common Questions, How to Join a Study) and a site revision label (Revision: v3.6.0); the header formatting around Intervention/Treatment was updated.SummaryDifference0.6%

- Check93 days agoChange DetectedThe page revision was updated from v3.5.4 to v3.5.5. This indicates a behind-the-scenes update to the study page's software or content management system.SummaryDifference0.1%

Stay in the know with updates to BBP-398 + Osimertinib in EGFR+ NSCLC: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the BBP-398 + Osimertinib in EGFR+ NSCLC: Clinical Trial page.